Posted by Michael Wonder on 12 Sep 2025
Johnson & Johnson seeks first EMA approval for icotrokinra aiming to transform the plaque psoriasis treatment paradigm
11 September 2025 - Johnson & Johnson today announced the submission of an application to the EMA seeking the first approval of icotrokinra, a first in class investigational targeted oral peptide that selectively blocks the IL-23 receptor for the treatment of adults and paediatric patients 12 years of age and older (adolescents) with moderate to severe plaque psoriasis.
Icotrokinra is an investigational targeted oral tablet that is designed to block the IL-23 receptor, which underpins the inflammatory response in psoriatic arthritis and offers potential in other IL-23-mediated diseases.
